Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada

PURPOSE: High‐strength opioid formulations were delisted (removed) from Ontario's public drug formulary in January 2017, except for palliative patients. We evaluated the impact of this policy on opioid utilization and dosing. METHODS: We conducted a longitudinal study among patients receiving p...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, Diana, Khuu, Wayne, Tadrous, Mina, Juurlink, David N., Mamdani, Muhammad M., Paterson, J. Michael, Gomes, Tara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518867/
https://www.ncbi.nlm.nih.gov/pubmed/30873707
http://dx.doi.org/10.1002/pds.4764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518867/
https://www.ncbi.nlm.nih.gov/pubmed/30873707
http://dx.doi.org/10.1002/pds.4764

Ejemplares similares